沙利度胺

沙利度胺 基本信息
CAS号 50-35-1 分子式 C13H10N2O4
分子量 258.22900 精确质量 　258.06400
PSA 　83.55000 LogP 　0.35450
我要卖该产品 我要采购该产品

等价的CAS号：

50-35-1,731-40-8,841-67-8,2614-06-4
充值推广 查看更多供应商
目录
基本信息 制备方法与用途 物化性质 安全信息 合成路线 毒性 MSDS 海关数据 结构与计算数据 上下游

基本信息 展开↓

CAS号：
50-35-1
3D弹球模型：
立即前往扯扯看
分子式：
C13H10N2O4
分子量：
258.22900
中文名称：
沙利度胺
英文名称：
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione
中文别名：
沙利度胺;
N-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺;
N-(2,6-二氧-3-哌啶基)邻苯二甲酰亚胺;
(±)-沙利度胺;
(±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione;
反应停;
(±)-Thalidomide
英文别名：
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione;
)-Thalidomide;
N-(2,6-Dioxo-3-piperidinyl)phthalimide;
2-(2,6-Dioxopiperidin-3-yl)isoindoline-1,3-dione;
Thalidomide
精确分子量/精确质量：
258.06400
极性分子表面积/PSA：
83.55000
油水分配系数/LogP：

LogP值指的是某物质在正辛醇/水两相体系中的分配系数的对数值，反映了物质在油水两相中的分配情况。其中、LogP值越大，说明该物质越亲油；反之，LogP值越小，则说明该物质越亲水。
贝尔斯坦号/MDL：
MFCD00153873
EINECS：
200-031-1
PubChem：
24278765
InChI：
InChI=1/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,1

生产制备方法及用途展开↓

制备方法

本品为谷氨酸衍生物，对麻风病无治疗作用，与抗麻风病药同用以减少麻风反应，治疗各型麻风反应，如淋巴结肿大、结节性红斑、发热、关节痛及神经痛等疗效较好。

用途简介

用途

对于各型麻风反应如发热、结节红斑、神经痛、关节痛、淋巴结肿大等有一定疗效，对结核样型的麻风反应疗效稍差。对麻风无治疗作用，可与抗麻风药同用以减少反应。制剂为片剂。本品有强烈致畸作用，妊娠禁忌。非麻风病患者不应使用此药。副作用有口干、头昏、恶心、腹痛等。


 

 

物化性质展开↓

外观与性状：
白色固体
密度：
1.503 g/cm3
熔点：
269-271°C
沸点：
509.7ºC at 760 mmHg
闪点：
262.1ºC
折射率：
1.646
存储条件/存储方法：

本品密封避光干燥保存。

其它信息：

1.       性状：淡黄色结晶性粉末，无臭，无味

2.       密度（g/mL,25/4℃）：未确定

3.       相对蒸汽密度（g/mL,空气=1）：未确定

4.       熔点（ºC）：269-271°C

5.       沸点（ºC,常压）：未确定

6.       沸点（ºC, 5.2 kPa）：未确定

7.       折射率：未确定

8.       闪点（ºC）：未确定

9.       比旋光度（º）：未确定

10.    自燃点或引燃温度（ºC）：未确定

11.    蒸气压（kPa,25 ºC）：未确定

12.    饱和蒸气压（kPa,60 ºC）：未确定

13.    燃烧热（KJ/mol）：未确定

14.    临界温度（ºC）：未确定

15.    临界压力（KPa）：未确定

16.    油水（辛醇/水）分配系数的对数值：未确定

17.    爆炸上限（%,V/V）：未确定

18.    爆炸下限（%,V/V）：未确定

19.    溶解性：微溶于水(<0.1 g/100 mL at 22 ºC)、乙醇、丙酮中，不溶于乙醚、氯仿。45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.6 mg/mL

 

安全信息展开↓

包装等级：
III
风险类别：
6.1(b)
海关代码：
2925190090
WGK_Germany：
3
德国有关水污染物质的分类清单
危险类别码：
R46;R61;R21;R25;R62
安全说明：
S53-S22-S26-S36/37/39-S45
RTECS号：
TI4375000
安全标志：
S53:避免暴露——使用前先阅读专门的说明。
S22:不要吸入粉尘。
S26:万一接触眼睛，立即使用大量清水冲洗并送医诊治。
:
S45:出现意外或者感到不适，立刻到医生那里寻求帮助（最好带去产品容器标签）。
危险标志：
T:Toxic

合成路线查看所有的合成路线

  • 3343-29-1

    N-α-邻苯二酰-L-谷氨酰胺

  • →

    ~93%

  • 50-35-1

    沙利度胺

  • 340-90-9

    N-邻苯二甲酰-L-谷氨酸

  • →

    ~85%

  • 50-35-1

    沙利度胺

  • 56-85-9

    L-谷氨酰胺

  • +

  • 131-11-3

    邻苯二甲酸二甲酯

  • →

    ~74%

  • 50-35-1

    沙利度胺

毒理性展开↓

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TI4375000
CHEMICAL NAME :
Phthalimide, N-(2,6-dioxo-3-piperidyl)-
CAS REGISTRY NUMBER :
50-35-1
BEILSTEIN REFERENCE NO. :
0030233
LAST UPDATED :
199706
DATA ITEMS CITED :
85
MOLECULAR FORMULA :
C13-H10-N2-O4
MOLECULAR WEIGHT :
258.25
WISWESSER LINE NOTATION :
T56 BVNVJ C- DT6VMVTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
113 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Administration onto the skin
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1550 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>6 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>5 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
>1538 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
21500 mg/kg/43W-I
TOXIC EFFECTS :
Peripheral Nerve and Sensation - recording from afferent nerve
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
34 gm/kg/57W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application Lungs, Thorax, or Respiration - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2 mg/kg
SEX/DURATION :
female 30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
17500 ug/kg
SEX/DURATION :
female 1-5 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2 mg/kg
SEX/DURATION :
female 29 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
16 mg/kg
SEX/DURATION :
female 28-35 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
560 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 10-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
500 mg/kg
SEX/DURATION :
female 7-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1050 mg/kg
SEX/DURATION :
female 1-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
28 gm/kg
SEX/DURATION :
male 3 day(s) pre-mating female 3 day(s) pre-mating - 22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
200 mg/kg
SEX/DURATION :
female 15 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - skin and skin appendages Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
1200 mg/kg
SEX/DURATION :
female 9-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
22 mg/kg
SEX/DURATION :
female 6-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
45 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - eye/ear
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
15 mg/kg
SEX/DURATION :
female 9-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
45 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
1700 mg/kg
SEX/DURATION :
female 6-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
750 mg/kg
SEX/DURATION :
female 2-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 mg/kg
SEX/DURATION :
female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 12-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
155 mg/kg
SEX/DURATION :
female 7-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
124 mg/kg
SEX/DURATION :
female 7-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
25 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
25 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
100 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
2 gm/kg
SEX/DURATION :
female 11-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
390 mg/kg
SEX/DURATION :
female 8-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
2 gm/kg
SEX/DURATION :
female 20-24 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
250 mg/kg
SEX/DURATION :
female 20-24 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 28 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
60 mg/kg
SEX/DURATION :
female 24-26 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
330 mg/kg
SEX/DURATION :
female 1-33 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
110 mg/kg
SEX/DURATION :
female 10-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
360 mg/kg
SEX/DURATION :
female 15-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion Reproductive - Specific Developmental Abnormalities - homeostasis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
150 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
450 mg/kg
SEX/DURATION :
female 7-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
450 mg/kg
SEX/DURATION :
female 7-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 7-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
833 mg/kg
SEX/DURATION :
female 6-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system Reproductive - Specific Developmental Abnormalities - gastrointestinal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
125 mg/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1500 mg/kg
SEX/DURATION :
female 6-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Specific Developmental Abnormalities - body wall
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1700 mg/kg
SEX/DURATION :
female 1-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1800 mg/kg
SEX/DURATION :
female 3-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1200 mg/kg
SEX/DURATION :
female 1-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
750 mg/kg
SEX/DURATION :
female 6-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
12500 ug/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
10 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
900 mg/kg
SEX/DURATION :
female 7-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - gastrointestinal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
1050 mg/kg
SEX/DURATION :
female 7-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
500 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
550 mg/kg
SEX/DURATION :
female 12-33 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
300 mg/kg
SEX/DURATION :
female 8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1500 mg/kg
SEX/DURATION :
female 8-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1800 mg/kg
SEX/DURATION :
female 13-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
Mutation test systems - not otherwise specified

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
7600 mg/kg/30D (Continuous)
REFERENCE :
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 202,1080,1964 *** REVIEWS *** TOXICOLOGY REVIEW BCSTB5 Biochemical Society Transactions. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1973- Volume(issue)/page/year: 2,695,1974 TOXICOLOGY REVIEW PLMJAP Pahlavi Medical Journal. (Shiraz, Iran) V.1-9, 1970-78. Volume(issue)/page/year: 6,160,1975 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 4(1),5,1974 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,365,1973 TOXICOLOGY REVIEW INTEAG Internist. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1960- Volume(issue)/page/year: 15,7,1974 TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 TOXICOLOGY REVIEW ATXKA8 Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher information, see ARTODN. Volume(issue)/page/year: 28,135,1971 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 267,1238,1962 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 267,1184,1962 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,45,1962 TOXICOLOGY REVIEW BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,646,1962 TOXICOLOGY REVIEW LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,303,1962

MSDS 展开↓

  (+/-)-沙利度胺
模块 1. 化学品
    产品名称：      (±)-Thalidomide    
  5.3
模块 2. 危险性概述
  GHS分类
    　物理性危害        未分类    
    　健康危害
    急性毒性（经口）      第3级    
    急性毒性（经皮）      第4级    
    生殖毒性      第2级    
    　环境危害        未分类    
  GHS标签元素
    　图标或危害标志
    　信号词        危险    
    　危险描述        吞咽会中毒。    
    皮肤接触有害
    怀疑会损害生育能力或胎儿
    　防范说明
  [预防]        使用前获取特定手册。    
    处理前必须阅读并理解所有安全措施。
    使用本产品时切勿吃东西，喝水或吸烟。
    处理后要彻底清洗双手。
  穿戴防护手套/护目镜/防护面具。
  [急救措施]      食入：立即呼叫解毒中心/医生。    
    皮肤接触：用大量肥皂和水轻轻洗。
    被污染的衣物清洗后方可重新使用。
  如接触到或相关接触：求医/就诊。
  [储存]        存放处须加锁。    
  [废弃处置]      根据当地政府规定把物品/容器交与工业废弃处理机构。    
  (+/-)-沙利度胺
模块 3. 成分/组成信息
  单一物质/混和物        单一物质    
  化学名(中文名)：      (+/-)-沙利度胺    
    百分比：      >98.0%(HPLC)(N)    
  CAS编码：      50-35-1    
    俗名：      N-(2,6-Dioxo-3-piperidinyl)phthalimide    
    分子式：      C13H10N2O4    
模块 4. 急救措施
    吸入：      将受害者移到新鲜空气处，保持呼吸通畅，休息。求医/就诊。    
    皮肤接触：      立即去除/脱掉所有被污染的衣物。用大量肥皂和水轻轻洗。    
  求医/就诊。
    眼睛接触：        用水小心清洗几分钟。如果方便，易操作，摘除隐形眼镜。    
  求医/就诊。
    食入：      立即呼叫解毒中心/医生。漱口。    
    紧急救助者的防护：        救援者需要穿戴个人防护用品，比如橡胶手套和气密性护目镜。    
模块 5. 消防措施
    合适的灭火剂：        干粉，泡沫，雾状水，二氧化碳    
    特殊危险性：        小心，燃烧或高温下可能分解产生毒烟。    
    特定方法：        从上风处灭火，根据周围环境选择合适的灭火方法。    
    非相关人员应该撤离至安全地方。
    周围一旦着火：如果安全，移去可移动容器。
    消防员的特殊防护用具：        灭火时，一定要穿戴个人防护用品。    
模块 6. 泄漏应急处理
    个人防护措施，防护用具，      使用特殊的个人防护用品（针对有毒颗粒的P3过滤式空气呼吸器）。远离溢出物/泄露    
    紧急措施：        处并处在上风处。    
    泄露区应该用安全带等圈起来，控制非相关人员进入。
    环保措施：        防止进入下水道。    
    控制和清洗的方法和材料：        清扫收集粉尘，封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的    
    法律法规处置。
模块 7. 操作处置与储存
    处理
    技术措施：        在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手    
    和脸。
    注意事项：        如果可能，使用封闭系统。如果粉尘或浮质产生，使用局部排气。    
    操作处置注意事项：        避免所有部位的接触！    
    贮存
    储存条件：        保持容器密闭。存放于凉爽、阴暗处。    
    存放处须加锁。
    远离不相容的材料比如氧化剂存放。
    包装材料：        依据法律。    
模块 8. 接触控制和个体防护
    工程控制：        尽可能安装封闭体系或局部排风系统。同时安装淋浴器和洗眼器。    
    个人防护用品
    　呼吸系统防护：      防尘面具，自携式呼吸器（SCBA），供气呼吸器等。使用通过政府标准的呼吸器。依    
    据当地和政府法规。
  (+/-)-沙利度胺
模块 8. 接触控制和个体防护
    　手部防护：        防渗手套。    
    　眼睛防护：        护目镜。如果情况需要，佩戴面具。    
    　皮肤和身体防护：        防渗防护服。如果情况需要，穿戴防护靴。    
模块 9. 理化特性
    固体
  外形（20°C）：
    外观：      晶体-粉末    
    颜色：      白色-极淡的黄色    
    气味：        无资料    
  pH:        无数据资料    
    熔点：      276°C    
  沸点/沸程        无资料    
    闪点：        无资料    
    爆炸特性
    　爆炸下限：        无资料    
    　爆炸上限：        无资料    
    密度：        无资料    
    溶解度：
  [水]      不溶于(60mg/L, 25°C)    
  [其他溶剂]
    易溶于：      二甲基甲酰胺, 吡啶, 二氧六环    
    极微溶于：      甲醇, 丙酮, 乙醇, 乙酸乙酯, 冰乙酸    
    不溶于：      醚, 苯, 氯仿    
  log水分配系数 =      3.09    
模块 10. 稳定性和反应性
    化学稳定性：        一般情况下稳定。    
    危险反应的可能性：        未报道特殊反应性。    
    须避免接触的物质        氧化剂    
  危险的分解产物:      一氧化碳, 二氧化碳, 氮氧化物 (NOx)    
模块 11. 毒理学信息
    急性毒性：      orl-rat LD50:113 mg/kg    
  skn-rat LD50:1550 mg/kg
  ipr-rat LD50:>6 g/kg
    对皮肤腐蚀或刺激：        无资料    
    对眼睛严重损害或刺激：        无资料    
    生殖细胞变异原性：      cyt-hmn-lym 1 mg/L    
  mmo-omi 10 g/L (-S9)
    致癌性：      scu-mus TDLo:34 g/kg/57W-I    
  IARC =        无资料    
  NTP =        无资料    
    生殖毒性：      orl-wmn TDLo:16 mg/kg(28-35D preg)    
  orl-rat TDLo:28 g/kg(3D male/3D pre-22D preg)
  ipr-rat TDLo:1200 mg/kg(9-11D preg)
  ivn-rat TDLo:45 mg/kg(12D preg)
  RTECS 号码:      TI4375000    
模块 12. 生态学信息
    生态毒性：
  (+/-)-沙利度胺
模块 12. 生态学信息
    鱼类：        无资料    
    甲壳类：        无资料    
    藻类：        无资料    
  残留性 / 降解性：        无资料    
  潜在生物累积 （BCF):        无资料    
    土壤中移动性
  　log水分配系数：      3.09    
  　土壤吸收系数 （Koc）：        无资料    
    　亨利定律        无资料    
  constant(PaM3/mol):
模块 13. 废弃处置
    如果可能，回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合，在装有后燃和洗涤装置的化学焚烧炉中
    焚烧。废弃处置时请遵守国家、地区和当地的所有法规。
模块 14. 运输信息
    联合国分类：      第1项 毒害品。    
  UN编号：      2811    
    正式运输名称：      有毒固体, 有机物, 不另作详细说明    
    包装等级：      III    
模块 15. 法规信息
  《危险化学品安全管理条例》（2002年1月26日国务院发布，2011年2月16日修订）: 针对危险化学品的安全使用、
    生产、储存、运输、装卸等方面均作了相应的规定。

模块16 - 其他信息
N/A

海关数据查看详细

中国海关编码：2925190090

概述：
2925190090 其他酰亚胺及其衍生物盐. 增值税率:17.0% 退税率:9.0% 监管条件:无 最惠国关税:6.5% 普通关税:30.0%
申报要素：
品名, 成分含量, 用途
摘要/Summary：
2925190090 other imides and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

分子结构与计算化学数据展开↓

分子结构数据

1、  摩尔折射率：62.35

2、  摩尔体积（cm3/mol）：171.7

3、  等张比容（90.2K）：496.5

4、  表面张力（dyne/cm）：69.9

5、  极化率（10-24cm3）：24.71

计算化学数据

1.疏水参数计算参考值（XlogP）:无

2.氢键供体数量:1

3.氢键受体数量:4

4.可旋转化学键数量:1

5.互变异构体数量:8

6.拓扑分子极性表面积83.6

7.重原子数量:19

8.表面电荷:0

9.复杂度:449

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:1

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

上下游相关产品

上游产品

更多

  • 3343-28-0

    N-酞酰基-DL-谷氨酸酐

  • 7607-72-9

    5-Amino-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxopentanoic acid

  • 85-44-9

    苯酐

  • 56-85-9

    L-谷氨酰胺

  • 131-11-3

    邻苯二甲酸二甲酯

下游产品

更多

  • 2614-06-4

    (+)-沙利度胺

  • 841-67-8

    (-)-沙利度胺

  • 145945-21-7

    2-[1-(hydroxymethyl)-2,6-dioxopiperidin-3-yl]isoindole-1,3-dione

  • 26581-81-7

    3-(1-Oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione

  • 220460-55-9

    2-(3-fluoro-2,6-dioxopiperidin-3-yl)isoindole-1,3-dione

立即下载安装“化学加”APP
专业、功能强大，随时调用更加方便
下载APP